View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Nov. 13, 2017
Document Information [Line Items]
Entity Registrant Name	Celsion Corp
Entity Central Index Key	0000749647
Trading Symbol	clsn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		16,062,341
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,685,010	$ 2,624,162
Investment securities – available for sale, at fair value		1,680,000
Accrued interest receivable on investment securities		4,008
Advances, deposits and other current assets	89,302	204,408
Subtotal current assets	2,774,312	4,512,578
Property and equipment (at cost, less accumulated depreciation and amortization of $2,854,122 and $2,513,022, respectively)	142,862	462,836
Other assets:
In-process research and development	20,246,491	22,766,491
Other intangible assets, net	852,437	1,022,924
Goodwill	1,976,101	1,976,101
Security deposit on letter of credit		100,000
Patent licensing fees and other assets, net	8,761	8,761
Subtotal other assets	23,083,790	25,874,277
Total assets	26,000,964	30,849,691
Current liabilities:
Accounts payable - trade	2,806,201	2,878,978
Other accrued liabilities	2,690,973	2,483,756
Notes payable - current portion		2,560,553
Deferred revenue – current portion	500,000	500,000
Subtotal current liabilities	5,997,174	8,423,287
Earn-out milestone liability	12,518,054	13,188,226
Deferred revenue – non-current portion	2,125,000	2,500,000
Other liabilities – non-current portion	73,680	12,352
Total liabilities	20,713,908	24,123,865
Commitments and contingencies
Stockholders’ equity:
Preferred Stock - $0.01 par value (100,000 shares authorized and no shares issued or outstanding at September 30, 2017 and December 31, 2016, respectively)
Common stock - $0.01 par value (112,500,000 shares authorized; 5,914,560 and 2,230,452 shares issued at June 30, 2017 and December 31, 2016, respectively, and 5,914,226 and 2,230,118 shares outstanding at June 30, 2017 and December 31, 2016, respectively)	83,555	22,305
Additional paid-in capital	262,389,735	248,168,421
Accumulated deficit	(257,101,046)	(241,379,712)
Subtotal	5,372,244	6,811,014
Treasury stock, at cost (334 shares at September 30, 2017 and December 31, 2016)	(85,188)	(85,188)
Total stockholders’ equity	5,287,056	6,725,826
Total liabilities and stockholders’ equity	$ 26,000,964	$ 30,849,691

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property and equipment, accumulated depreciation	$ 2,854,122	$ 2,513,022
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	100,000	100,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	112,500,000	112,500,000
Common stock, shares issued (in shares)	8,355,013	2,230,452
Common stock, shares outstanding (in shares)	8,354,679	2,230,118
Treasury stock, shares (in shares)	334	334

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Licensing revenue	$ 125,000	$ 125,000	$ 375,000	$ 375,000
Operating expenses:
Research and development	3,348,847	4,225,132	9,870,754	11,002,675
General and administrative	1,174,250	1,496,471	4,291,482	4,888,301
Total operating expenses	4,523,097	5,721,603	14,162,236	15,890,976
Loss from operations	(4,398,097)	(5,596,603)	(13,787,236)	(15,515,976)
Other income (expense):
Gain (loss) from change in valuation of earn-out milestone liability	1,246,151	(662,410)	670,172	(556,382)
Loss from impairment of in-process research and development	(2,520,000)		(2,520,000)
Investment income, net	524	8,133	3,941	21,832
Interest expense		(161,025)	(91,756)	(608,576)
Other income	93	2,218	3,545	1,965
Total other expense, net	(1,273,232)	(813,084)	(1,934,098)	(1,141,161)
Net loss	(5,671,329)	(6,409,687)	(15,721,334)	(16,657,137)
Deemed dividend related to warrant modification			(345,685)
Net loss attributable to common shareholders	$ (5,671,329)	$ (6,409,687)	$ (16,067,019)	$ (16,657,137)
Net loss per common share
Basic and diluted (in dollars per share)	$ (0.70)	$ (3.22)	$ (3.04)	$ (9.27)
Weighted average shares outstanding
Basic and diluted (in shares)	8,054,658	1,993,233	5,171,699	1,796,184

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net loss	$ (5,671,329)	$ (6,409,687)	$ (15,721,334)	$ (16,657,137)
Other comprehensive (loss) gain
Realized loss on investment securities recognized in investment income, net				3,858
Unrealized gain on investment securities		464		464
Other comprehensive gain		464		4,322
Comprehensive loss	$ (5,671,329)	$ (6,409,223)	$ (15,721,334)	$ (16,652,815)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (15,721,334)	$ (16,657,137)
Non-cash items included in net loss:
Depreciation and amortization	511,587	365,625
Change in fair value of earn-out milestone liability	(670,172)	556,382
Impairment of in-process research and development	2,520,000
Deferred revenue	(375,000)	(375,000)
Stock-based compensation costs	951,488	1,331,094
Shares issued out of treasury		79,238
Amortization of deferred finance charges and debt discount associated with notes payable	35,370	198,806
Change in deferred rent liability	61,328	(25,981)
Loss realized on sale of investment securities		3,858
Net changes in:
Accrued interest on short term investments	4,008	22,205
Advances, deposits and other current assets	115,106	(136,871)
Accounts payable	(72,777)	195,716
Accrued liabilities	207,217	725,660
Net cash (used in) operating activities:	(12,433,179)	(13,716,405)
Cash flows from investing activities:
Proceeds from sale and maturity of investment securities	1,680,000	10,800,000
Purchases of investment securities		(4,515,125)
Refund of security for letter of credit	100,000
Purchases of property and equipment	(21,126)	(48,928)
Net cash provided by investing activities	1,758,874	6,235,947
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs	8,405,190	5,428,965
Proceeds from exercise of common stock warrants, net of issuance costs	4,925,886
Principal payment and end of term charges on note payable	(2,595,923)	(3,029,429)
Net cash provided by financing activities	10,735,153	2,399,536
Increase (decrease) in cash and cash equivalents	60,848	(5,080,922)
Cash and cash equivalents at beginning of period	2,624,162	9,265,144
Cash and cash equivalents at end of period	2,685,010	4,184,222
Supplemental disclosures of cash flow information:
Interest paid	$ 56,386	$ 409,996

Note 1 - Business Description

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Nature of Operations [Text Block]

Note

Business Description

Celsion Corporation,

a Delaware corporation based in Lawrenceville, New Jersey, its wholly-owned subsidiaries CLSN Laboratories, Inc., also a Delaware corporation, and Celsion GmbH, a limited liability company in Zug Switzerland, referred to herein as “Celsion”, “we”, or “the Company”, as the context requires, is a fully-integrated development stage oncology drug company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. We are working to develop and commercialize more efficient, effective and targeted oncology therapies based on our technologies, with the goal of developing novel therapeutics that maximize efficacy while minimizing side effects common to many cancer treatments.

Our lead product candidate is ThermoDox®, a proprietary dosage form of doxorubicin based on a heat-activated liposomal platform technology, currently in a Phase III clinical trial for the treatment of non-resectable hepatocellular carcinoma (“HCC”) also known as primary liver cancer. Our pipeline includes GEN-

a DNA-based immunotherapy currently in a Phase I clinical trial for the localized treatment of ovarian cancer and pre-clinical development for brain cancer. GEN-

is based on a platform technology for the development of treatments using novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

Note 2 - Basis of Presentation

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Basis of Accounting [Text Block]

Note

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements, which include the account

s of Celsion Corporation, CLSN Laboratories, Inc. and Celsion GmbH, have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial information and with the instructions to Form

-Q and Article

of Regulation S-

All intercompany balances and transactions have been eliminated. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.

In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements. Oper

ating results for the

three

and

nine

month periods ended

September 30, 2017

are

not

necessarily indicative of the results that

may

be expected for any other interim period(s) or for any full year. For further information, refer to the financial statements and notes thereto included in the Company’s Annual Report on Form

-K for the fiscal year ended

December 31, 2016

filed with the Securities and Exchange Commission (SEC) on

March 24, 2017.

The preparation of financial statements in conformity with GAAP

requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from those estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes.

events and conditions would give rise to any information that required accounting recognition or disclosure in the financial statements other than those arising in the ordinary course of business.

As more fully described in Note

10,

the Company effected a

-for-

reverse stock split of its common stock on

May 26, 2017

which was made effective for trading purposes as of the commencement of trading on

May 30, 2017.

All prior period shares of common stock have been adjusted to reflect the

-for-

reverse stock split.

Note 3 - Financial Condition and Business Plan

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Substantial Doubt about Going Concern [Text Block]

Note

Financial Condition

and Business Plan

Since inception, the Company has incurred

substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s product candidates, and applications and submissions to the Food and Drug Administration (FDA) among other international regulatory authorities. We have incurred approximately

$257

million of cumulated net losses. As of

September 30, 2017,

we had approximately

$2.7

million in cash and cash equivalents. As discussed in Note

16,

October 4, 2017,

we entered into exercise agreements with certain warrant holders whereby these warrant holders would exercise

4.7

million warrants at their respective strike prices of

$2.07

and

$4.75

per share and the Company issued to these warrant holders

1.2

million new warrants at an exercise price of

$6.20

per warrant share. The exercise of these warrants, coupled with the exercise of

0.3

million additional warrants provided the Company with

$17.0

million in gross proceeds. Also as discussed in Note

16,

October 27, 2017,

we entered into an underwriting agreement whereby the Company sold approximately

2.6

million shares of common stock and warrants to purchase approximately

1.3

million shares of common stock for gross proceeds of

$6.6

million.

We have substantial future capital requirements

associated with our continued research and development activities and to advance our product candidates through various stages of development. The Company believes these expenditures are essential for the commercialization of its technologies.

The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company

’s control. These factors include the following:

●

the progress of research

activities;

●

the number and scope of research programs;

●

the progress of preclinical and clinical development activities;

●

the progress of the development efforts of parties with whom the Company has entered into research and development agreements;

●

the costs associated with additional clinical trials of product candidates;

●

the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;

●

the ability to

achieve milestones under licensing arrangements;

●

the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and

●

the costs and timing of regulatory approvals.

The Company has based its estimate on assumptions that

may

prove to be wrong. The Company

may

need to obtain additional funds sooner or in greater amounts than it currently anticipates.

Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders

may

be diluted.

With the

$2.7

million in cash and investments on hand at

September 30, 2017

combined with the gross proceeds of $

23.6

million provided by the exercise of warrants and the equity offering in

October 2017 (

Note

), the Company believes it has sufficient capital resources to fund its operations well into the

second

quarter of

2019.

The Company will be required to obtain additional funding in order to continue the development of its current product candidates within the anticipated time periods, if at all, and to continue to fund operations. As more fully discussed in Note

10,

the Company has

$7.5

million available under a controlled equity offering facility it has with Cantor Fitzgerald & Co. Besides this equity facility, the Company does

not

have any committed sources of financing at this time, and there is uncertainty whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company would

not

be able to obtain financing when needed, it could be unable to carry out the business plan and

may

have to significantly limit its operations, and its business, financial condition and results of operations could be materially harmed. With the current cash on hand and the gross proceeds of

$23.6

million from warrant exercises and the equity offering in

October, 2017,

management believes the Company will be able to meet its obligations as they come due.

Note 4 - New Accounting Pronouncements

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

Note

New Accounting Pronouncements

From time to time, new accounting pronouncements are

issued by Financial Accounting Standards Board (FASB) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will

not

have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do

not

apply to our operations.

May 2014,

the FASB issued Accounting Standards Update

(ASU)

No.

2014

“Revenue from Contracts with Customers (Topic

606

),” which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. ASU

2014

was originally going to be effective on

January

2017;

however, the FASB issued ASU

2015

14,

“Revenue from Contracts with Customers (Topic

606

) — Deferral of the Effective Date,” which deferred the effective date of ASU

2014

one

year to

January

2018.

March

2016,

the FASB issued ASU

No.

2016

“Revenue from Contracts with Customers (Topic

606

): Principal versus Agent Considerations. The amendments in this ASU do

not

change the core principle of ASU

No.

2014

but the amendments clarify the implementation guidance on reporting revenue gross versus net. The effective date for the amendments in this ASU is the same as the effective date of ASU

No.

2014

09.

April

2016,

the FASB issued ASU

No.

2016

10,

“Revenue from Contracts with Customers (Identifying Performance Obligations and Licensing),” to clarify the implementation guidance on identifying performance obligations and licensing. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. The Company plans to adopt the standard on

January 1, 2018

using the modified retrospective approach. The Company will conduct its contract review process throughout the remainder of

2017

and make appropriate changes to business and control processes to support recognition and disclosure under the new standard. Based on the Company’s evaluation to date, the adoption of the ASU

2014

not

expected to have a material impact on its consolidated financial statements because existing contractual performance obligations, which determine when and how revenue is recognized, are

not

materially changed under the new standard. Additionally, the Company is also working on the expanded disclosures related to revenue recognition as required by the new standard.

January 2016,

the FASB issued Accounting Standards Update

No.

2016

01,

Recognition and Measurement

of Financial Assets and Financial Liabilities, which requires that most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income (other than those accounted for under the equity method of accounting). This guidance is effective for fiscal years, and interim periods within those years, beginning after

December 15, 2017.

Based on the Company’s evaluation to date, the adoption of the ASU

2016

not

expected to have a material impact on its consolidated financial statements or its disclosures.

February 2016,

the FASB issued Accounting Standards Update

No.

2016

02,

Leases (Topic

842

), which requires that lessees recognize assets and liabilities for leases with lease terms greater than

twelve

months in the statement of financial position. Leas

es will be classified as either finance or operating, with classification affecting the pattern of expense recognition in

the income statement. This update also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after

December 15, 2018,

including interim reporting periods within that reporting period. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this guidance will have on its consolidated financial statements and disclosures.

March 2016,

the FASB issued Accounting Standards Update

No.

2016

09,

Compensation

– Stock Compensation (Topic

718

). The new standard simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The new standard is effective for public companies for annual reporting periods beginning after

December 15, 2016,

including interim periods within those annual reporting periods; however, early adoption is allowed. The Company adopted this standard in

January 2017

and made the election to account for award forfeitures as they occur. The adoption of this standard did

not

have a material impact on the Company’s consolidated financial statements.

August 2016,

the FASB issued Accounting Standard Update

No.

016

15,

Statement of Cash Flows (Topic

230

): Classification of Certain Cash Receipts and Cash Payments. This update clarifies how certain cash receipts and payments should be presented in the statement of cash flows and is effective for interim and annual reporting periods beginning after

December 15, 2017,

with early adoption permitted. Based on the Company’s evaluation to date, the adoption of the ASU

2016

not

expected to have a material impact on its consolidated financial statements or its disclosures.

November 2016,

the FASB issued Accounting Standard Update

No.

2016

18,

Statement of Cash Flows (Topic

230

): Restricted Cash. This update amends the guidance in ASC

230,

including providing additional guidance related to transfers between cash an

d restricted cash and how entities present, in their statement of cash flows, the cash receipts and cash payments that directly affect the restricted cash accounts. This guidance is effective for annual reporting periods beginning after

December 15, 2017,

and interim periods within those years, with early adoption permitted. Based on the Company’s evaluation to date, the adoption of the ASU

2016

not

expected to have a material impact on its consolidated financial statements or its disclosures.

In Ja

nuary

2017,

the FASB issued Accounting Standard Update

No.

2017

01,

Business Combinations (Topic

805

): Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This guidance is effective for annual reporting periods beginning after

December 15, 2018,

and interim periods within those years, with early adoption permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.

January 2017,

the FASB issued Accounting Standard Update

No.

2017

04,

Intangibles-Goodwill and Other, Simplifying the Test for Goodwill i

mpairment, which eliminates Step

from the goodwill impairment test. Under the revised test, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should

not

exceed the total amount of goodwill allocated to that reporting unit. This ASU is effective for any interim or annual impairment tests for fiscal years beginning after

December 15, 2019,

with early adoption permitted. The Company adopted this method for its impairment test of goodwill during

2017.

Note 5 - Net Loss Per Common Share

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Earnings Per Share [Text Block]

Note

Net Loss per Common Share

Basic loss per

share is calculated based upon the net loss available to common shareholders divided by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method.

The total num

ber of shares of common stock issuable upon exercise of warrants and equity awards was

6,208,386

shares for the

three

and

nine

month periods ended

September 30, 2017.

For the

three

and

nine

month periods ended

September 30, 2017,

diluted loss per common share was the same as basic loss per common share as all options and all warrants that were exercisable into shares of the Company’s common stock were excluded from the calculation of diluted earnings attributable to common shareholders per common share as their effect would have been anti-dilutive.

For the

three

and

nine

month periods ended

September 30, 2016,

the total number of shares of common stock issuable upon exercise of warrants and equity awards was

1,353,312

shares. The Pre-funded Series B Warrants (as more fully described in Note

of these financial statements) exercisable into shares of the Company’s common stock totaling

132,142

shares was considered issued in calculating basic loss per share. For the

three

and

nine

month periods ended

September 30, 2016,

diluted loss per common share was the same as basic loss per common share as the other

1,221,168

warrants and equity awards that were exercisable into shares of the Company’s common stock were excluded from the calculation of diluted loss per common share as their effect would have been anti-dilutive.

Note 6 - Fair Value of Measurements

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note

Fair Value of Measurements

FASB Accounting Standards Codification (ASC) Section

820

“

Fair Value Measurements and Disclosures,”

establishes a

three

level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The

three

levels of inputs that

may

be used to measure fair value are as follows:

Level

: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date;

Level

: Significant other observable inputs other than Level

prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are

not

active; or other inputs that are observable or can be corroborated by observable market data; and

Level

: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability.

The fair values of securities available for sale are determined by obtaining quoted prices on nationally recognized exchanges (Level

inputs) or m

atrix pricing, which is a mathematical technique widely used in the industry to value debt securities without relying exclusively on quoted prices for the specific securities but rather by relying on the securities’ relationship to other benchmark quoted securities (Level

inputs).

Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the balance sheet at their estimated fair values primarily due to their short-term nature. There were

transfer

s of assets of liabilities between Level

and Level

and

transfers in or out of Level

during the

nine

months ended

September 30, 2017

except for the change in the earn-out milestone liability included in earnings (Note

Assets and liabili

ties measured at fair value are summarized below:

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Recurring items as of December 31, 2016 Investment securities, available for sale	$	1,680,000	$	1,680,000	$	─	$	─

Liabilities:
Recurring items as of September 30, 2017 Earn-out milestone liability (Note 12)	$	12,518,054	$	─	$	─	$	12,518,054

Recurring items as of December 31, 2016 Earn-out milestone liability (Note 1 2)	$	13,188,226	$		$		$	13,188,226

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 7 - Acquisition of EGEN Assets

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Business Combination Disclosure [Text Block]

Note

Acquisition

of EGEN Assets

June

20,

2014,

we completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama corporation, which has changed its company name to EGWU, Inc. after the closing of the acquisition (“EGEN”), pursuant to an asset purchase agreement dated as of

June

2014,

by and between EGEN and Celsion (the “Asset Purchase Agreement”). We acquired all of EGEN’s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date.

The total purchase price for the asset acquisition is up to

$44.4

million, including potential future earnout payments of up to

$30.4

million contingent upon achievement of certain earnout milestones set forth in the Asset Purchase Agreement. At the closing, we paid approximately

$3.0

million in cash after the expense adjustment and issued

193,728

shares of our common stock to EGEN. The shares of common stock were issued in a private transaction exempt from registration under the Securities Act, pursuant to Section

(

) thereof. In addition,

47,862

shares of common stock were held back by us at the closing and are issuable to EGEN pending satisfactory resolution of any post-closing adjustments for expenses or in relation to EGEN’s indemnification obligations under the Asset Purchase Agreement. These shares were issued on

June 16, 2017.

The earnout payments of up to

$30.4

million will become payable, in cash, shares of our common stock or a combination thereof, at our option upon achievement of

three

major milestone events as follows:

●

$12.4

million will become payable upon achieving certain specified development milestones relating to an ovarian cancer study of GEN-

(formerly known as EGEN-

001

) to be conducted by us or our subsidiary;

●

$12.0

million will become payable upon achieving certain specified development milestones relating to a GEN-

glioblastoma multiforme brain cancer study to be conducted by us or our subsidiary; and

●

up to

$6.0

million will become payable upon achieving certain specified milestones relating to the TheraSilence technology acquired from EGEN in the acquisition.

The following table summarizes the fair values of these assets acquired and liabilities assumed related to the acquisition.

Property and equipment, net	$	35,000
In-process research and development		24,211,000
Other intangible assets (Covenant not to compete)		1,591,000
Goodwill		1,976,000
Total assets		27,813,000
Accounts payable and accrued liabilities		(235,000	)
Net assets acquired	$	27,578,000

Acquired In-Process Research and Development (IPR&D) consists of EGEN's drug technology platforms

known as “TheraPlas” and “TheraSilence”. The fair value of the IPR&D drug technology platforms was estimated to be

$24.2

million as of the acquisition date using the Multi-Period Excess Earnings Method (MPEEM). Under the MPEEM, the fair value of an intangible asset is equal to the present value of the asset’s incremental after-tax cash flows (excess earnings) remaining after deducting the market rates of the return of the estimated value of contributory assets (contributory charge) over its remaining useful life. As of the closing of the acquisition, the IPR&D is considered indefinite lived intangible assets and will

not

be amortized.

IPR&D is reviewed for impairment at least annually as of our

third

quarter ended

September 30,

and whenever events or changes in circumstances indicate that the carrying value

of the assets might

not

be recoverable.

December 31, 2016,

the Company determined

one

of the IPR&D assets related to the development of its RNA delivery system being developed with collaborators using their RNA product candidates, valued at

$1.4

million, was impaired. Therefore, the Company wrote off the value of this IPR&D asset incurring a non-cash charge of

$1.4

million in the

fourth

quarter of

2016.

September 30, 2017,

after the Company’s assessment of the totality of the events that could impair IPR&D, the Company determined certain IPR&D assets related to the development of its glioblastoma multiforme cancer (GBM) product candidate

may

be impaired. To arrive at this determination, the Company assessed the status of studies in GBM conducted by its competitors and the Company’s strategic commitment of resources to its studies in primary liver cancer and ovarian cancer. The Company estimated the fair value of the IPR&D related to GBM at

September 30, 2017

using the MPEEM. The Company concluded that the GBM asset, valued at

$9.4

million, was partially impaired and wrote down the GBM asset to

$6.9

million incurring a non-cash charge of

$2.5

million in the

third

quarter of

2017.

In connection with the writeoff of this IPR&D asset, the Company concluded there was a reduced probability of payments of the earn-out milestones associated with the GBM asset and therefore reduced the earn-out milestone liability from

$13.8

million to

$12.5

million, recording a non-cash benefit of approximately

$1,246,151

in the

third

quarter of

2017.

The Company concluded

none

of the other IPR&D assets were impaired at

September 30, 2017.

Pursuant to the EGEN Purchase Agreement, EGEN provided certain covenants (“Covenant

Not

To Compete”) to the Company whereby EGEN agreed, during the period ending on the

seventh

anniversary of the closing date of the acquisition on

June 20, 2014,

not

to enter into any business, directly or indirectly, which competes with the business of the Company nor will it contact, solicit or approach any of the employees of the Company for purposes of offering employment.

Amortization expense was

$56,829

and

$170,487

during the

three

months and

nine

months ended

September 30, 2017,

respectively. The carrying value of the Covenant

Not

To Compete was

$852,437,

net of

$738,777

accumulated amortization, as of

September 30, 2017

and was

$1,022,924,

net of

$568,290

accumulated amortization, as of

December 31, 2016.

The purchase price exceeded the estimated fair

value of the net assets acquired by approximately

$2.0

million which was recorded as Goodwill. Goodwill represents the difference between the total purchase price for the net assets purchased from EGEN and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed. Goodwill is reviewed for impairment at least annually as of our

third

quarter ended

September 30

or sooner if we believe indicators of impairment exist.

As of

September 30,

201

we concluded that the Company’s fair value exceeded its carrying value therefore “it is

not

more likely than

not”

that the Goodwill was impaired.

Note 8 - Accrued Liabilities

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note

Accrued Liabilities

Other accrued liabilities at

September 30, 2017

and

December 31, 2016

include the following:

	September 30, 2017		December 31, 2016
Amounts due to contract research organizations and other contractual agreements	$	907,850	$	1,115,193
Accrued payroll and related benefits		1,514,253		1,066,751
Accrued professional fees		248,850		259,551
Accrued interest on notes payable		–		22,241
Other		20,020		20,020
Total	$	2,690,973	$	2,483,756

Note 9 - Note Payable

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Debt Disclosure [Text Block]

Note

Note Payable

November 2013,

the Company entered into a loan agreement with Hercules

Technology Growth Capital, Inc. (Hercules) which permits up to

$20

million in capital to be distributed in multiple tranches (the Hercules Credit Agreement). The Company drew the

first

tranche of

million upon closing of the Hercules Credit Agreement in

November 2013

and used approximately

million of the proceeds to repay the outstanding obligations under its loan agreement with Oxford Finance LLC and Horizon Technology Finance Corporation as discussed further below. On

June 10, 2014,

the Company closed the

second

million tranche under the Hercules Credit Agreement. The proceeds were used to fund the

$3.0

million upfront cash payment associated with Celsion's acquisition of EGEN, as well as the Company’s transaction costs associated with the EGEN acquisition. Upon the closing of this

second

tranche, the Company has drawn down a total of

$10

million under the Hercules Credit Agreement.

The obligations under the Hercules Credit Agreement were in the form of secured indebtedness bearing interest at

a calculated prime-based variable rate (

11.25%

per annum since inception through

December 17, 2015

and

11.50%

since). Payments under the loan agreement were interest only for the

first

twelve

months after loan closing, followed by a

-month amortization period of principal and interest through the scheduled maturity date of

June 1, 2017.

In connection with the Hercules Credit Agreement, the Company incurred cash expenses of

$122,378.

Also in connection with the Hercules Credit Facility, the Company paid loan origination fees of

$230,000.

Collectively, these deferred fees have been classified as a direct deduction from the debt liability consistent with the presentation of a debt discount and are being amortized as interest expense using the effective interest method over the life of the loan.

As a fee in connection with the Hercules Credit Agreement, the Company issued Hercules a warrant for a total of

6,963

shares of the Company

’s common stock (the Hercules Warrant) at a per share exercise price of

$50.26,

exercisable for cash or by net exercise from

November 25, 2013.

Upon the closing of the

second

tranche on

June 10, 2014,

this warrant became exercisable for an additional

6,963

shares of the Company’s common stock. The Hercules Warrant will expire

November 25, 2018.

Hercules has certain rights to register the common stock underlying the Hercules Warrant pursuant to a Registration Rights Agreement with the Company dated

November 25, 2013.

The registration rights expire on the date when such stock

may

be sold under Rule

144

without restriction or upon the

first

year anniversary of the registration statement for such stock, whichever is earlier. The common stock issuable pursuant to the Hercules Warrant was filed pursuant to Rule

415

under the Securities Act of

1933

on the Prospectus for Registration Statement

No.

333

193936

and was declared effective on

September 30, 2014.

The Company valued the Hercules Warrants issued using the Black-Scholes option pricing model and recorded a total of

$476,261

as a direct deductions from the debt liability consistent with the presentation of a debt discount and are being amortized as interest expense using the effective interest method over the life of the loan. Also in connection with each of the

$5.0

million tranches, the Company is required to pay an end of term charge equal to

3.5%

of each original loan amount at time of maturity. Therefore, these amounts totaling

$350,000

were amortized as interest expense using the effective interest method over the life of the loan.

The loan balance and end of term charges on the Hercules Credit Agreement was paid in full in

June 2017.

For the

three

month periods ended

September 30, 2017

and

2016,

the Company incurred

and

$107,805

in interest expense, respectively, and amortized

and

$53,220,

respectively as interest expense for deferred fees, debt discount and end of term charges in connection with the Hercules Credit Agreement. For the

nine

month periods ended

September 30, 2017

and

2016,

the Company incurred

$56,386

and

$409,770

in interest expense, respectively, and amortized

$35,370

and

$198,806,

respectively as interest expense for deferred fees, debt discount and end of term charges in connection with the Hercules Credit Agreement.

Note 10 - Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Note

Stockholders

’ Equity

September 2015,

the Company filed with the Securities and Exchange Commission (the SEC) a

$75

million shelf registration statement on Form S-

(the

2015

Shelf Registration Statement) (File

No.

333

206789

) that

allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock or preferred stock. This shelf registration was declared effective on

September 25, 2015.

At the

2016

Annual Meeting of Stockholders of the

Company in

June 2016,

the Company’s stockholders of the Company approved an increase in the number of the authorized shares of the Company’s common stock from

75,000,000

shares to

112,500,000

shares. The number of the authorized shares of preferred stock remained at

100,000

shares. The aggregate number of shares of all classes of stock that the Company

may

issue, after giving effect to such amendment as approved by the stockholders, is

112,600,000

shares.

Reverse Stock Split

May 26, 2017,

the Company effected a

-for-

reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on

May 30, 2017.

As of that date, each

shares of issued and outstanding common stoc

k and equivalents was consolidated into

one

share of common stock. In addition, at the market open on

May 30, 2017,

the Company’s common stock started trading under a new CUSIP number

15117N503

although the Company’s ticker symbol, CLSN, remained unchanged.

The reverse stock split was previously approved by the Company

’s stockholders at the

2017

Annual Meeting held on

May 16, 2017,

and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the amendment are:

	●	To increase the market price of the Company ’s common stock making it more attractive to a broader range of institutional and other investors, and
	●	To provide the Company with additional capital resources and flexibility sufficient to execute its business plans including the establishment of strategic relationships with other companies and to ensure its ability to raise additional capital as necessary.

Immediately prior to the reverse stock split, the Company had

56,982,418

shares of common stock outstanding which consolidated into

4,070,172

shares of the Company

’s common stock.

fractional shares were issued in connection with the reverse stock split. Holders of fractional shares have been paid out in cash for the fractional portion with the Company’s overall exposure for such payouts consisting of a nominal amount. The number of outstanding options and warrants were adjusted accordingly, with outstanding options being reduced from approximately

2.4

million to approximately

0.2

million and outstanding warrants being reduced from approximately

33.5

million to approximately

2.4

million.

July 6, 2017

Common Stock Offering

July 6, 2017,

the Company e

ntered into a securities purchase agreement with several investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering, an aggregate of

2,050,000

shares of common stock of the Company at an offering price of

$2.07

per share for gross proceeds of

$4,243,500

before the deduction of the placement agent fee and offering expenses. In addition, the Company sold Pre-Funded Series CCC Warrants to purchase

385,000

shares of common stock (and the shares of common stock issuable upon exercise of the Pre-Funded Series CCC Warrants), in lieu of shares of common stock to the extent that the purchase of common stock would cause the beneficial ownership of the Purchaser, together with its affiliates and certain related parties, to exceed

9.99%

of our common stock. The Pre-Funded Series CCC Warrants were sold at an offering price of

$2.06

per share for gross proceeds of

$793,100,

are immediately exercisable for

$0.01

per share of common stock and do

not

have an expiration date. In a concurrent private placement, the Company agreed to issue to each investor, for each share of common stock and pre-funded warrant purchased in the offering, a Series AAA Warrant and Series BBB Warrant, each to purchase

one

share of common stock. The Series AAA Warrants are initially exercisable

six

months following issuance, and terminate

five

and

one

-half years following issuance. The Series AAA Warrants have an exercise price of

$2.07

per share and are exercisable to purchase an aggregate of

2,435,000

shares of common stock. The Series BBB Warrants are immediately exercisable following issuance, and terminate

twelve

months following issuance. The Series BBB Warrants have an exercise price of

$4.75

per share and are exercisable to purchase an aggregate of

2,435,000

shares of common stock. Subject to limited exceptions, a holder of a Series AAA and Series BBB Warrant will

not

have the right to exercise any portion of its warrants if the holder, together with its affiliates, would beneficially own in excess of

9.99%

of the number of shares of common stock outstanding immediately after giving effect to such exercise.

During the

third

quarter of

2017,

all

385,000

of the Series CCC Pre-Funded warrants were exercised in full.

As more fully described in Note

15,

all the Series AAA and Series BBB Warrants were exercised as their respective strike prices in

October 2017

and the Company received

$16.6

million in gross proceeds.

February 14, 2017

Public Offering

February 14, 2017,

the Company entered into a securities purchase agreement whereby it sold, in a public offering (the

February 14, 2017

Public Offering), an aggregate of

1,384,704

shares of common stock of the Company at an offering price of

$3.22

per

share. In addition, the Company sold Series AA Warrants (the Series AA Warrants) to purchase up to

1,177,790

shares of common stock and Pre-Funded Series BB Warrants (the Pre-Funded Series BB Warrants) to purchase up to

185,713

shares of common stock. The Series AA Warrants have an exercise price of

$3.22

per share, have a

five

year life and are immediately exercisable. The Pre-Funded Series BB Warrants were offered at

$3.08

per share, were immediately exercisable for

$0.14

per share of common stock, do

not

have an expiration date and were issued in lieu of shares of common stock to the extent that the purchase of common stock would cause the beneficial ownership of the purchaser of such shares, together with its affiliates and certain related parties, to exceed

9.99%

of our common stock. The Company received approximately

$5.0

million in gross proceeds before the deduction of the placement agent fees and offering expenses (excluding any proceeds from the exercise of the warrants) in the

February 14, 2017

Public Offering.

In connection with the

February 14, 2017

Public Offering, the Company filed with the Securities and Exchange Commission a registration statement on Form

S-

(Registration

No.

333

215321

) on

December 23, 2016,

as amended by Pre-Effective Amendment

No.

filed with the Commission on

January 20, 2017,

as further amended by Pre-Effective Amendment

No.

filed with the Commission on

February 13, 2017,

as further amended by Pre-Effective Amendment

No.

filed with the Commission on

February 13, 2017

and as further amended by Pre-Effective Amendment

No.

filed with the Commission on

February 14, 2017

for the registration of the securities issued and sold under the Securities Act of

1933,

as amended.

During the

first

nine

months of

2017,

all

185,713

of the Series BB Pre-Funded warrants were exercised in full. During the

first

nine

months of

2017,

we received approximately

$2.1

million from the exercise of Series AA Warrants to purchase

638,809

shares of common stock.

December 2016

Common Stock Of

fering

December 20, 2016,

the Company entered into a securities purchase agreement with certain investors, pursuant to which the Company sold and issued on

December 23, 2016,

in a registered direct offering, an aggregate of

367,346

shares of the

Company’s common stock at an offering price of

$4.90

per share for gross proceeds of approximately

$1.8

million before the deduction of the placement agent fee and offering expenses (the

“December 2016

Offering”). In a concurrent private placement (the “Private Placement Transaction”), the Company agreed to issue to the investors certain warrants at an exercise price of

$6.44

per share (the

December 2016

Warrants). The

December 2016

Warrants are exercisable to purchase common stock for an aggregate of

367,343

shares of common stock. The warrants are initially exercisable

six

months following issuance and terminate

five

and

one

-half years following the date of issuance. The

December 2016

Warrants

may

be exercised from time to time beginning on

June 20, 2017

and expire on

June 20, 2022.

April 5, 2017,

the Company filed a registration statement on Form S-

for the resale of any share of common stock issued upon exercise of the

December 2016

Warrants on Form S-

(File

No.

333

217156

) which was declared effective by the SEC on

April 19, 2017.

As more fully discussed below, all the

December 2016

Warrants were exercised in

June 2017.

The private placement of the

December 2016

Warrants was structured to comply with the requirements of Section

(a)(

) under the

Securities Act and Rule

506

(b) promulgated thereunder.

June 2016

Common Stock Offering

June 13, 2016,

the Company entered into a securities purchase agreement with investors, pursuant to which the Company issued and sold, in a registered direct off

ering, an aggregate of

165,126

shares of common stock, par value

$0.01

per share, of the Company at an offering price of

$19.04

per share for gross proceeds of approximately

$6.0

million before the deduction of the placement agent fee and offering expenses. In a concurrent private placement, the Company issued to the investor Series A warrants (the

“June 2016

Series A Warrants”), each to purchase

0.5

share of the Company’s common stock, Series C warrants (the

“June 2016

Series C Warrants”), each to purchase

one

share of the Company’s common stock, and Series D warrants (the

“June 2016

Series D Warrants”), each to purchase

0.5

share of the Company’s common stock (collectively, the

“June 2016

Warrants”). The

June 2016

Series A Warrants are initially exercisable

six

months following issuance and terminate

five

and

one

-half years following issuance. The

June 2016

Series C Warrants are initially exercisable

six

months following issuance and terminate

one

year following issuance. The

June 2016

Series D Warrants only become exercisable ratably upon the exercise of the

June 2016

Series C Warrants, are initially exercisable

six

months following issuance, and terminate

five

and

one

-half years following issuance. The

June 2016

Warrants have an exercise price of

$19.60

per share and are exercisable to purchase an aggregate of

630,252

shares of Common Stock. On

October 31, 2016,

the Company filed a registration statement on Form S-

for the resale of any share of common stock issued upon exercise of the warrants on Form S-

(File

No.

333

212353

) which was declared effective by the SEC on

November 16, 2016.

As more fully discussed below, all the

June 2016

Warrants were exercised in

June 2017.

The private placement of the

June 2016

Warrants was structured to comply with th

e requirements of Section

(a)(

) under the Securities Act and Rule

506

(b) promulgated thereunder.

Reduced Exercise Price of Warrants

February 22, 2013,

the Company entered into a securities purchase agreement with certain investors pursuant to which the Company agreed, among other things, to issue warrants (the “

2013

Warrants”) to purchase up to

95,811

shares of our common stock at an exercise price of

$74.34

per share to such investors in a registered direct offering. On

January 15, 2014,

the Company entered into a securities purchase agreement with certain investors pursuant to which the Company agreed, among other things, to issue warrants (the

“2014

Warrants”) to purchase up to

64,348

shares of our common stock at an exercise price of

$57.40

per share to such investors in a registered direct offering. On

June 9, 2017,

the Company entered into warrant exercise agreements (the “Exercise Agreements”) with certain holders of the

2013

Warrants, the

2014

Warrants and the

June 2016

Warrants (the “Exercising Holders”), which Exercising Holders own, in the aggregate, warrants exercisable for

790,410

shares of our common stock. Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that the Exercising Holders would exercise their

2013

Warrants, the

2014

Warrants and the

June 2016

Warrants with respect to

790,410

shares of our common stock underlying such warrants for a reduced exercise price equal to

$2.70

per share. The Company received aggregate gross proceeds of approximately

$2.1

million from the exercise of the

2013

Warrants, the

2014

Warrants and the

June 2016

Warrants by the Exercising Holders.

The reduced e

xercise price of the

2013

Warrants, the

2014

Warrants and the

June 2016

Series C Warrants increased the fair value of the warrants by approximately

$0.2

million. This increase in fair value is recorded as a deemed dividend in additional paid in capital due to the retained deficit increased the net loss available to common shareholders on the consolidate statement of operations.

May 27, 2015

entered into a securities purchase agreement with certain investors pursuant to which the Company agreed, among o

ther things, to issue warrants (the

“2015

Warrants”) to purchase up to

139,284

shares of the Company’s common stock at an exercise price of

$36.40

per share, to such investors in a registered direct offering. Between

June 22, 2017

through

June 26, 2017,

the Company and holders of the

2015

Warrants and the

December 2016

Warrants (the Exercising Investors) entered into agreements whereby the Company agreed that the Exercising investors would exercise their

2015

Warrants and the

June 2016

Warrants with respect to

506,627

shares of our common stock underlying such warrants for a reduced exercise price equal to

$1.65

per share. The Company received aggregate gross proceeds of approximately

$0.8

million from the exercise of the

2015

Warrants and the

June 2016

Warrants by the Exercising Investors.

The reduced exercise price of the

2015

Warrants increased the fair value of the warrants by approximately

$0.1

million. This increase in fair value is recorded as a deemed dividend in additional paid in capital due to th

e retained deficit increased the net loss available to common shareholders on the consolidate statement of operations.

Controlled Equity Offering

February 1, 2013,

the Company entered into a Controlled Equity Offering SM Sales Agreement (the “

ATM Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which Celsion

may

offer and sell, from time to time, through Cantor, shares of our common stock having an aggregate offering price of up to

$25.0

million (the “ATM Shares”) pursuant to the Company’s previously filed and effective Registration Statement on Form S-

Under the ATM Agreement, Cantor

may

sell ATM Shares by any method deemed to be an “at-the-market” offering as defined in Rule

415

promulgated under the Securities Act of

1933,

as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for the our common stock or to or through a market maker. From

February 1, 2013

through

September 30, 2017,

the Company sold and issued an aggregate of

105,678

shares of common stock under the ATM Agreement, receiving approximately

$7.6

million in gross proceeds. In connection with the

October 2017

Offering discussed below (Note

), the Company has agreed

not

to sell any additional shares under the ATM Agreement for a period of

two

months after the closing of the

October 2017

Offering which occurred on

October 31, 2017.

The Company is

not

obligated to sell any ATM Shares under the ATM Agreement.

Subject to the terms and conditions of the ATM Agreement, Cantor will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The NASDAQ Capital Market, to sell ATM Shares from time to time based upon the Company’s instructions, including any price, time or size limits or other customary parameters or conditions the Company

may

impose. In addition, pursuant to the terms and conditions of the ATM Agreement and subject to the instructions of the Company, Cantor

may

sell ATM Shares by any other method permitted by law, including in privately negotiated transactions.

The ATM Agreement will terminate upon the earlier of (i) the sale of ATM Shares under the ATM Agreement having an aggregat

e offering price of

$25

million and (ii) the termination of the ATM Agreement by Cantor or the Company. The ATM Agreement

may

be terminated by Cantor or the Company at any time upon

days' notice to the other party, or by Cantor at any time in certain circumstances, including the occurrence of a material adverse change in the Company. The Company pays Cantor a commission of

3.0%

of the aggregate gross proceeds from each sale of ATM Shares and has agreed to provide Cantor with customary indemnification and contribution rights. The Company also reimbursed Cantor for legal fees and disbursements of

$50,000

in connection with entering into the ATM Agreement.

October 2, 2015,

we filed a prospectus supplement to the base prospectus that forms a part of the

2015

Shelf Registration Statement, pursuant to which we

may

offer and sell up to

$7.5

million of shares of common stock from time to time under the ATM Agreement of the

$17.4

million remaining under the ATM Agreement.

Note 11 - Stock-based Compensation

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note

Stock-Based Compensation

Stock Options Plans

The Company has long-term compensation plans that permit the granting of incentive awards in the form of stock options. Generally, the terms of these plans require that the exercise price of the options

may

not

be less than the fai

r market value of Celsion’s common stock on the date the options are granted. Options granted generally vest over various time frames or upon milestone accomplishments. The Company’s options generally expire

ten

years from the date of the grant.

The Cel

sion Corporation

2007

Stock Incentive Plan (the

2007

Plan), as adopted and amended, permits the granting of

688,531shares

of stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, and performance awards, or in any combination of the foregoing.

2007,

the Company adopted the Celsion Corporation

2007

Stock Incentive Plan (the

2007

Plan) under which

15,873

shares were authorized for

issuance. The purpose of the

2007

Plan is to promote the long-term growth and profitability of the Company by providing incentives to improve stockholder value and enable the Company to attract, retain and reward the best available persons for positions of substantial responsibility. The

2007

Plan permits the granting of equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, and performance awards, or in any combination of the foregoing. At the Annual Meetings of Stockholders of Celsion held on

June 25, 2010,

June 7, 2012,

June 20, 2014,

and

May 16, 2017

the stockholders approved amendments to the Plan. The only material difference between the original Plan and the amended Plan was the number of shares of common stock available for issuance under the amended Plan which was increased by

15,873

to a total of

31,746

shares in

2010,

35,714

to a total of

67,460

shares in

2012,

178,571

to a total of

246,031

shares in

2014

and by

442,500

to a total of

688,531

shares in

2017.

Prior to the

adoption of the

2007

Plan, the Company adopted

two

stock plans for directors, officers and employees (

one

2001

and another in

2004

) under which

21,164

shares collectively were reserved for future issuance under both of these plans. As these plans have been superseded by the

2007

Plan, any options previously granted which expire, forfeit, or cancel under these plans will be rolled into the

2007

Plan.

A summary

of the Company’s stock option and restricted stock awards for the

nine

months ended

September 30, 2017

is as follows:

	Stock Options					Restricted Stock Awards					Weighted Average
Equity Awards	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding			Weighted Average Grant Date Fair Value		Contractual Terms of Equity Awards (in years)

Equity awards outstanding at December 31, 2016		210,023		$	59.77		4,785		$	37.42

Equity awards granted		513,464		$	2.69		(3,357	)		42.20

Equity awards forfeited, cancelled or expired		(43,735	)	$	164.12		(1,428	)	$	26.18

Equity awards outstanding at September 30, 2017		679,752		$	9.94		–		$	–		9.40

Aggregate intrinsic value of outstanding awards at September 30, 2017	$	–				$	–

Equity awards exercisable at September 30, 2017		401,920		$	13.83							9.13

Aggregate intrinsic value of awards exercisable at September 30, 2017	$	–

The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the

fair value of traded options, which have different characteristics from Celsion’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate.

The Company used the following assumptions fo

r determining the fair value of options granted during the

nine

months ended

September 30, 2017

and

2016

under the Black-Scholes option pricing model:

	Nine Months Ended September 30,
	2017			2016
Risk-free interest rate		2.21	%	1.55	–	1.87%
Expected volatility		90.4	%	87.4	–	89.1%
Expected life (in years)		10.00			10.00
Expected forfeiture rate		─	%		10%
Expected dividend yield		─	%		─%

Expected volatilities utilized in the model are based on historical volatility of the Company

’s stock price. The risk free interest rate is derived from values assigned to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant. The model incorporated exercise, pre-vesting and post-vesting forfeiture assumptions based on analysis of historical data for forfeitures through FY

2016.

Starting in FY

2017,

the Company made the election to account for any forfeitures when they occur. The expiration of each option granted in fiscal

2016

and

2017

was used as the expected life.

Total compensation cost related to employee stock options and restricted stock awards totaled $

146,896

and

$432,573

for the

three

months ended

September 30, 2017

and

2016,

respectively. Total compensation cost related to employee stock options and restricted stock awards totaled

$951,488

and

$1,331,094

for the

nine

months ended

September 30, 2017

and

2016,

respectively.

compensation cost related to share-based payments arrangements was capitalized as part of the cost of any asset as of

September 30, 2017

and

2016.

As of

September 30, 2017,

there was

$0.5

million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of

1.1

years. The weighted average grant-date fair value was

$2.69

and

16.24

per share for the options granted during the

nine

months ended

September 30, 2017

and

2016,

respectively.

Collectively, for all of the Company

’s stock option plans there were a total of

29,498

equity awards available for future issuance as of

September 30, 2017.

Note 12 - Earn-out Milestone Liability

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Earn-out Milestone Liability Disclosure [Text Block]

Note

Earn-out Milestone Liability

The total aggregate purchase price for the EGEN Acquisition included potential future Earn-out Payments contingent upon achievement of certain milestones. The difference between the aggregate

$30.4

million in future Earn-out Payments

and the

$13.9

million included in the fair value of the acquisition consideration at

June 20, 2014

was based on the Company's risk-adjusted assessment of each milestone (

10%

67%

) and utilizing a discount rate based on the estimated time to achieve the milestone (

1.5

2.5

years). The earn-out milestone liability will be fair valued at the end of each quarter and any change in their value will be recognized in the condensed consolidated financial statements.

As of

September 30, 2017,

June 30, 2017

and

December 31, 2016,

the Company fair valued these milestones at

$12.5

million,

$13.8

million and

$13.2

million, respectively, and recognized a non-cash benefit of

$1,246,151

and

$670,172

during the

three

and

nine

months ended

September 30, 2017

as a result of the change in the fair value of these milestones from the beginning of each period respectively.

As of

September 30, 2016,

June 30, 2016

and

December 31, 2015,

the Company fair valued these milestones at

$14.5

million,

$13.8

million and

$13.9

million, respectively, and recognized a non-cash charge of

$662,410

and

$556,382

during the

three

and

nine

month periods ended

September 30, 2016,

respectively, as a result of the change in the fair value of these milestones from the beginning of each period respectively.

The

following is a summary of the changes in the earn-out milestone liability for

2017:

Balance at January 1, 2017	$	13,188,226
Non-cash benefit from the adjustment for the change in fair value included in net loss		(1,246,151	)
Balance at September 30, 2017	$	12,518,054

The following is a schedule of the Company

’s risk-adjustment assessment of each milestone:

Date	Risk-adjustment Assessment of each Milestone				Discount Rate			Estimated Time to Achieve (years)

September 30, 2017		35%	to	80%		9	%		1.25	to	1.75
June 30, 2017		50%	to	80%		9	%		1.50	to	2.00
December 31, 2016		50%	to	80%		9	%		2.00	to	2.50

September 30, 2016		10%	to	75%		9	%		0.50	to	1.75
June 30, 2016		10%	to	75%		9	%		0.50	to	2.00
December 31, 2015		10%	to	75%		9	%		0.50	to	2.50

Note 13 - Warrants

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Warrants [Text Block]

Note

Warrants

Common Stock Warrants

Following is a summary of all warrant activity for the

nine

months ended

September 30, 2017:

Warrants	Number of Warrants Issued			Weighted Average Exercise Price

Warrants outstanding at December 31, 2016		1,487,958		$	9.39
Warrants issued during the nine months ended September 30, 2017 (see Note 10)		6,679,378			3.08
Warrants exercised during the nine months ended September 30, 2017 (see Note 10)		(2,638,702	)		1.92

Warrants outstanding at September 30, 2017		5,528,634		$	5.33

Aggregate intrinsic value of outstanding warrants at September 30, 2017	─

Weighted average remaining contractual terms at September 30, 2017 (in years)		3.16

Note 14 - Contingent Liabilities and Commitments

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Note

Contingent Liabilities and Commitments

July 2011,

the Company executed a lease (the “

Lease”) with Brandywine Operating Partnership, L.P. (Brandywine), a Delaware limited partnership for a

10,870

square foot premises located in Lawrenceville, New Jersey. In

October 2011,

the Company relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland. The lease has a term of

months and provides for

months of rent free, with the

first

monthly rent payment of approximately

$23,000

due and paid in

April 2012.

Also, as required by the Lease, the Company provided Brandywine with an irrevocable and unconditional standby letter of credit for

$250,000,

which the Company secured with an escrow deposit at its banking institution of this same amount. The standby letter of credit will be reduced by

$50,000

on each of the

19th,

31st

and

43rd

months from the initial term, with the remaining

$100,000

amount remaining until the Lease term has expired. In connection with

three

$50,000

reductions of the standby letter of credit in

April 2013

and

2014

and

2015,

the Company reduced the escrow deposit by

$50,000

each time. In late

2015,

Lenox Drive Office Park LLC, purchased the real estate and office building and assumed the lease. This lease was set to expire on

April 30, 2017.

April 2017,

the Company and the landlord amended the Lease effective

May 1, 2017.

The Lease amendment extended the term for an additional

months, reduced the premises to

7,565

square feet, reduced the monthly rent and provided

four

months free rent. The monthly rent will range from approximately

$18,900

in the

first

year to approximately

$20,500

in the final year of the amendment. The Company also has a

one

-time option to cancel the lease as of the

24th

month after the commencement date of the Lease amendment.

In connection with the EGEN Asset Purchase agreement in

June 2014,

the Company assumed the existing lease with another landlord for an

11,500

square foot premise

s located in Huntsville Alabama. This lease has a remaining term of

four

months with rent payments of approximately

$23,200

per month. The Company is currently in discussions with the landlord to extend and modify its lease in Huntsville, Alabama.

Note 15 - Technology Development and Licensing Agreements

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Licensing Transaction [Text Block]

Technology Development and Licensing Agreements

May 7, 2012

the Company entered into a long term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun) for the production of ThermoDox®

in the China territory. In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical transfer costs, Celsion consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox®. Celsion will repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of

three

registration batches of ThermoDox®. Hisun is also obligated to certain performance requirements under the agreement. The agreement will initially be limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, Hisun will collaborate with Celsion around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration (CHINA FDA). During the

first

quarter of

2015,

Hisun completed the successful manufacture of

three

registration batches of ThermoDox® and the Company accrued

$685,787

for the aggregate development costs and fees associated with these batches in

March 2015.

This amount was paid in

April 2015.

January 18, 2013,

we entered into a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable research and

development fee of

million to support our development of ThermoDox ® in mainland China, Hong Kong and Macau (the China territory). Following our announcement on

January 31, 2013

that the HEAT study failed to meet its primary endpoint, Celsion and Hisun have agreed that the Technology Development Contract entered into on

January 18, 2013

will remain in effect while the parties continue to collaborate and are evaluating the next steps in relation to ThermoDox®, which include the sub-group analysis of patients in the Phase III HEAT Study for the hepatocellular carcinoma clinical indication and other activities to further the development of ThermoDox ® for the Greater China market. The

$5.0

million received as a non-refundable payment from Hisun in the

first

quarter

2013

has been recorded to deferred revenue and will continue to be amortized over the

year term of the agreement, until such time as the parties find a mutually acceptable path forward on the development of ThermoDox® based on findings of the ongoing post-study analysis of the HEAT Study data.

July 19, 2013,

the Company and Hisun entered into a Memorandum of Understanding to pursue ongoing collaborations for the continued clinical development of ThermoDox®

as well as the technology transfer relating to the commercial manufacture of ThermoDox® for the China territory. This expanded collaboration includes development of the next generation liposomal formulation with the goal of creating safer, more efficacious versions of marketed cancer chemotherapeutics.

Among the key provisions of the Celsion-Hisun Memorandum of Understanding are:

	●	Hisun will provide the Company with non-dilutive financing and the investment necessary to complete the technology transfer of its proprietary manufacturing process and the production of registration batches for the China territory;

	●	Hisun will collaborate with the Company around the clinical and regulatory approval activities for ThermoDox® as well as other liposomal formations with the CHINA FDA; and

	●	Hisun will be granted a right of first offer for a commercial license to ThermoDox® for the sale and distribution of ThermoDox® in the China territory.

August 8, 2016,

we signed a Technology Transfer,

Manufacturing and Commercial Supply Agreement (“GEN-

Agreement”) with Hisun to pursue an expanded partnership for the technology transfer relating to the clinical and commercial manufacture and supply of GEN-

Celsion’s proprietary gene mediated, IL-

immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of the world after all necessary regulatory approvals are in effect. The GEN-

Agreement will help to support supply for both ongoing and planned clinical studies in the U.S., and for potential future studies of GEN-

in China. GEN-

is currently being evaluated by Celsion in

first

line ovarian cancer patients.

Key provisions of the GEN-

Agreement are as follows:

	●	the GEN- 1 Agreement has targete d unit costs for clinical supplies of GEN- 1 that are substantially competitive with the Company’s current suppliers;

	●	once approved, the cost structure for GEN- 1 will support rapid market adoption and significant gross margins across global markets;

	●	Celsion will provide Hisun a certain percentage of China ’s commercial unit demand, and separately of global commercial unit demand, subject to regulatory approval;

	●	Hisun and Celsion will commence technology transfer activities relating to the manufacture of GEN- 1, including all studies required by CFDA for site approval; and

	●	Hisun will collaborate with Celsion around the regulatory approval activities for GEN- 1 with the CFDA. A local China partner affords Celsion access to accelerated CFDA review and potential regulatory exclusivity for the approved indication.

Note 16 - Subsequent Events

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Subsequent Events [Text Block]

Note

Subsequent Events

October 2017

Warrant Exercises

October 4, 2017,

the Company entered into letter agreements (the “Exercise Agreements”) with the holders of the Series AAA and Series BBB Warrants issued in the

July 6, 2017

Common Stock Offering (the “Exercising Holders”)

(Note

). The Exercise Agreements amended the Series AAA Warrants to permit their immediate exercise. Prior to the execution of the Exercise Agreements, the Series AAA Warrants were

not

exercisable until

January 11, 2018.

Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that the Exercising Holders would exercise all of their Existing Warrants with respect to

4,665,000

shares of Common Stock underlying such Existing Warrants. The Series AAA Warrants and Series BBB Warrants were exercised at a price of

$2.07

per share and

$4.75

per share, respectively, which were their respective original exercise prices.

The Exercise Agreements also provide for the issuance of

1,166,250

Series DDD Warrants, each to purchase

one

share of Common Stock (the “Series DDD Warrants”). The Series DDD Warrants are initially exercisable

sooner than

six

months following issuance, and terminate

six

months following when the Series DDD Warrants are initially exercisable. The Series DDD Warrants have an exercise price

than less than

$6.20.

The Series DDD Warrants and the shares of Common Stock issuable upon the exercise of the Series DDD Warrants are

not

being registered under the Securities Act of

1933,

as amended (the “Securities Act”), and are being offered pursuant to the exemption provided in Section

(a)(

) under the Securities Act or Rule

506

(b) promulgated thereunder. Pursuant to the Exercise Agreements, the Series DDD Warrants shall be substantially in the form of the Existing Warrants and the Company will be required to register for resale the shares of Common Stock underlying the Series DDD Warrants.

In early

October 2017,

certain holders of the other

205,000

Series BBB Warrants and

108,455

Series AA Warrants from the

February 14, 2017

Public Offering (Note

) were exercised and, together with the exercise of the

4,665,000

Series AAA and Series BBB Warrants exercised by the Exercising Holders, the Company received aggregate gross proceeds of approximately

$20.0

million in

October 2017.

October 2017

Underwritten Offering

October 27, 2017,

the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc. (the “Underwriter”), relating to the issuance and sale (the “Offering”) of

2,640,000

shares (the “Shares”) of the Company’s common stock,

$0.01

par value per share (the “Common Stock”), and warrants to purchase an aggregate of

1,320,000

shares of Common Stock. Each share of Common Stock is being sold together with

0.5

warrants (the “Investor Warrants”), each whole Investor Warrant being exercisable for

one

share of Common Stock, at an offering price of

$2.50

per share and related Investor Warrants.

Pursuant to the terms of the Underwriting Agreement, the Underwriter has agreed to purchase the Shares and related

Investor Warrants from the Company at a price of

$2.325

per share and related Investor Warrants. Each Investor Warrant is exercisable

six

months from the date of issuance. The Investor Warrants have an exercise price of

$3.00

per whole share, and expire

five

years from the date

first

exercisable.

The

Company received

$6.6

million of gross proceeds from the sale of the Shares and Investor Warrant. The Offering closed on

October 31, 2017.

This Offering was made pursuant to the Company’s effective shelf registration statement on Form S-

(File

No.

333

206789

) filed with the Securities and Exchange Commission on

September 4, 2015,

and declared effective on

September 25, 2015,

including the base prospectus dated

September 25, 2017

included therein and the related prospectus supplement.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties, and termination provisions.

The Company also agreed to issue to the Underwriter warrants to purchase up to

66,000

shares of the Company’s common stock, such issuance being exempt from registration pursuant to Section

(a)(

) of the Securities Act.

Note 6 - Fair Value of Measurements (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Recurring items as of December 31, 2016 Investment securities, available for sale	$	1,680,000	$	1,680,000	$	─	$	─

Liabilities:
Recurring items as of September 30, 2017 Earn-out milestone liability (Note 12)	$	12,518,054	$	─	$	─	$	12,518,054

Recurring items as of December 31, 2016 Earn-out milestone liability (Note 1 2)	$	13,188,226	$		$		$	13,188,226

Note 7 - Acquisition of EGEN Assets (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Property and equipment, net	$	35,000
In-process research and development		24,211,000
Other intangible assets (Covenant not to compete)		1,591,000
Goodwill		1,976,000
Total assets		27,813,000
Accounts payable and accrued liabilities		(235,000	)
Net assets acquired	$	27,578,000

Note 8 - Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2017		December 31, 2016
Amounts due to contract research organizations and other contractual agreements	$	907,850	$	1,115,193
Accrued payroll and related benefits		1,514,253		1,066,751
Accrued professional fees		248,850		259,551
Accrued interest on notes payable		–		22,241
Other		20,020		20,020
Total	$	2,690,973	$	2,483,756

Note 11 - Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Share-based Compensation Stock Options and Restricted Stock Awards Activity [Table Text Block]

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; margin-left: 18pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Stock Options</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restricted Stock</div></div></div> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Awards</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12.95pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12.95pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"><div style="display: inline; font-weight: bold;">Equity Awards</div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Non-vested</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Restricted</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Stock</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Grant</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Date</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10.8pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair Value</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12.95pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12.95pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Terms of</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12.95pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Equity</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12.95pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Awards</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12.95pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in years)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Equity awards outstanding at December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">210,023</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,785</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Equity awards granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">513,464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0.8pt 0pt 0pt; text-align: left;">)</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">42.20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Equity awards forfeited, cancelled or expired</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(43,735</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 6.95pt 0pt 0pt; text-align: left;">)</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">164.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,428</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 2.4pt 0pt 0pt; text-align: left;">)</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.18</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Equity awards outstanding at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">679,752</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.94</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Aggregate intrinsic value of outstanding awards at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Equity awards exercisable at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401,920</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Aggregate intrinsic value of awards exercisable at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> </table></div>

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Nine Months Ended September 30,
	2017			2016
Risk-free interest rate		2.21	%	1.55	–	1.87%
Expected volatility		90.4	%	87.4	–	89.1%
Expected life (in years)		10.00			10.00
Expected forfeiture rate		─	%		10%
Expected dividend yield		─	%		─%

Note 12 - Earn-out Milestone Liability (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Changes in Earn out Milestone Liabilities [Table Text Block]

Schedule of Milestone Risk Adjustment Assessment [Table Text Block]

Date	Risk-adjustment Assessment of each Milestone				Discount Rate			Estimated Time to Achieve (years)

September 30, 2017		35%	to	80%		9	%		1.25	to	1.75
June 30, 2017		50%	to	80%		9	%		1.50	to	2.00
December 31, 2016		50%	to	80%		9	%		2.00	to	2.50

September 30, 2016		10%	to	75%		9	%		0.50	to	1.75
June 30, 2016		10%	to	75%		9	%		0.50	to	2.00
December 31, 2015		10%	to	75%		9	%		0.50	to	2.50

Note 13 - Warrants (Tables)	9 Months Ended
Note 13 - Warrants (Tables)	Sep. 30, 2017
Notes Tables
Schedule of Warrant Activity [Table Text Block]	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0px" cellpadding="0pt" cellspacing="0pt" style="margin: 0pt 2.5%; font-size: 10pt; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 68%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"><div style="display: inline; font-weight: bold;">Warrants</div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.5pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.5pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrants</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.5pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Issued</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.5pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.5pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.5pt;margin-top:0pt;text-align:right;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Warrants outstanding at December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,487,958</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.39</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Warrants issued during the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">nine months ended September 30, 2017 (see Note 10)</div></div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,679,378</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.08</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Warrants exercised during the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">nine months ended September 30, 2017 (see Note 10)</div></div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,638,702</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 2.8pt 0pt 0pt; text-align: left;">)</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Warrants outstanding at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,528,634</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="padding-left: 9pt; text-indent: -9pt;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Aggregate intrinsic value of outstanding warrants at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0.8pt 0pt 0pt; text-align: right;">─</div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Weighted average remaining contractual terms at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017 (in years)</div></div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.16</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> </table></div>

Note 2 - Basis of Presentation (Details Textual)	May 26, 2017
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	14

Note 3 - Financial Condition and Business Plan (Details Textual) - USD ($)				1 Months Ended	9 Months Ended	28 Months Ended	55 Months Ended
	Oct. 27, 2017	Oct. 04, 2017	Oct. 02, 2015	Oct. 31, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2017	Jun. 26, 2017	Jun. 09, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Retained Earnings (Accumulated Deficit)					$ (257,101,046)	$ (257,101,046)	$ (257,101,046)			$ (241,379,712)
Cash and Cash Equivalents, at Carrying Value					$ 2,685,010	$ 2,685,010	$ 2,685,010			$ 2,624,162	$ 4,184,222	$ 9,265,144
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5.33	$ 5.33	$ 5.33	$ 1.65	$ 2.70	$ 9.39
Class of Warrant or Right, Issued During Period					6,679,378
Proceeds from Warrant Exercises						$ 800,000	$ 2,100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								506,627	790,410
Aggregate Offering Price, Additions			$ 7,500,000
Subsequent Event [Member]
Proceeds from Issuance of Common Stock and Warrant Exercises				$ 23,600,000
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member]
Stock Issued During Period, Shares, Additional Exercise of Warrants		300,000
Proceeds from Warrant Exercises		$ 17,000,000
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series AAA and Series BBB Warrants [Member]
Class of Warrant or Right, Exercised During Period		4,665,000
Proceeds from Warrant Exercises		$ 20,000,000
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series AAA Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.07
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series BBB Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		4.75
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series DDD Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.20
Class of Warrant or Right, Issued During Period		1,166,250
Subsequent Event [Member] \| October 2017 Undwriting Offering [Member]
Stock Issued During Period, Shares, New Issues	2,640,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,300,000
Proceeds from Issuance of Common Stock and Warrants	$ 6,600,000

Note 5 - Net Loss Per Common Share (Details Textual) - shares	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Number of Shares of Common Stock Issuable Upon Exercise of Warrants and Equity Awards	6,208,386	1,353,312

Note 6 - Fair Value of Measurements (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2017 USD ($)
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3	$ 0

Note 6 - Fair Value of Measurements - Assets and Liabilities at Fair Value on a Recurring Basis (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Earn-out milestone liability	$ 12,518,054	$ 13,188,226
Fair Value, Measurements, Recurring [Member]
Short-term investments, fair value		1,680,000
Earn-out milestone liability	12,518,054	13,188,226
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Short-term investments, fair value		1,680,000
Earn-out milestone liability
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Short-term investments, fair value
Earn-out milestone liability	$ 12,518,054	$ 13,188,226

Note 7 - Acquisition of EGEN Assets (Details Textual) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 16, 2017	Jun. 20, 2014	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Jun. 30, 2017
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)			$ 2,520,000		$ 2,520,000
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability					(1,246,151)
Finite-Lived Intangible Assets, Net			852,437		852,437		$ 1,022,924
Noncompete Agreements [Member]
Amortization of Intangible Assets			56,829		170,487
Finite-Lived Intangible Assets, Net			852,437		852,437		1,022,924
Finite-Lived Intangible Assets, Accumulated Amortization			738,777		738,777		$ 568,290
EGEN Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 30,400,000	30,400,000		30,400,000
Payments to Acquire Businesses, Gross		$ 3,000,000
Stock Issued During Period, Shares, Acquisitions		193,728
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	47,862
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability			1,246,151	$ 662,410	670,172	$ 556,382
Goodwill, Acquired During Period		$ 2,000,000
EGEN Inc [Member] \| Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life							7 years
EGEN Inc [Member] \| Indefinite-lived in Process Research and Development [Member]
Indefinite-lived Intangible Assets Acquired		24,200,000	6,900,000		9,400,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)							$ 1,400,000
Asset Impairment Charges			2,500,000
Business Combination, Contingent Consideration, Liability			12,500,000		12,500,000			$ 13,800,000
EGEN Inc [Member] \| Ovarian Cancer Study Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			12,400,000		12,400,000
EGEN Inc [Member] \| Glioblastoma Multiforme Brain Cancer Study Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			12,000,000		12,000,000
EGEN Inc [Member] \| TheraSilence Technology Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 6,000,000		$ 6,000,000
EGEN Inc [Member] \| Maximum [Member]
Business Combination, Consideration Transferred		$ 44,400,000

Note 7 - Acquisition of EGEN Assets - Summary of Estimated Fair Values of Acquired Assets and Liabilities (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Jun. 20, 2014
Goodwill	$ 1,976,101	$ 1,976,101
EGEN Inc [Member]
Property and equipment, net			$ 35,000
In-process research and development			24,211,000
Other intangible assets (Covenant not to compete)			1,591,000
Goodwill			1,976,000
Total assets			27,813,000
Accounts payable and accrued liabilities			(235,000)
Net assets acquired			$ 27,578,000

Note 8 - Accrued Liabilities - Other Accrued Liabilities (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Amounts due to contract research organizations and other contractual agreements	$ 907,850	$ 1,115,193
Accrued payroll and related benefits	1,514,253	1,066,751
Accrued professional fees	248,850	259,551
Accrued interest on notes payable		22,241
Other	20,020	20,020
Total	$ 2,690,973	$ 2,483,756

Note 9 - Note Payable (Details Textual) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		17 Months Ended	26 Months Ended	47 Months Ended
Note 9 - Note Payable (Details Textual) - USD ($)	Jun. 20, 2014	Jun. 10, 2014	Nov. 30, 2013	Sep. 30, 2017	Sep. 30, 2016	Jun. 10, 2014	Sep. 30, 2017	Sep. 30, 2016	May 31, 2017	Dec. 17, 2015	Sep. 30, 2017	Jun. 26, 2017	Jun. 09, 2017	Dec. 31, 2016	Jun. 30, 2015	Nov. 25, 2013
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5.33			$ 5.33				$ 5.33	$ 1.65	$ 2.70	$ 9.39
Hercules Warrant [Member]
Debt Instrument, Unamortized Discount		$ 476,261				$ 476,261
EGEN Inc [Member]
Payments to Acquire Businesses, Gross	$ 3,000,000
Hercules Credit Agreement [Member]
Repayments of Lines of Credit			$ 4,000,000
Interest Expense, Debt				$ 0	$ 107,805		$ 56,386	$ 409,770
Amortization of Debt Issuance Costs				0	$ 53,220		35,370	$ 198,806
Hercules Credit Agreement [Member] \| Hercules Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																$ 50.26
Line of Credit Facility Original Loan Fee Percent															3.50%
Debt Issuance Costs, Gross															$ 350,000
Hercules Credit Agreement [Member] \| EGEN Inc [Member]
Payments to Acquire Businesses, Gross		3,000,000
Hercules [Member]
Repayments of Lines of Credit		$ 5,000,000
Hercules [Member] \| Hercules Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity			20,000,000
Proceeds from Lines of Credit			5,000,000			$ 10,000,000
Debt Instrument, Basis Spread on Variable Rate									11.50%	11.25%
Amortization Period for Principal and Interest											2 years 180 days
Debt Issuance Costs, Net				$ 122,378			$ 122,378				$ 122,378
Debt Instrument, Unamortized Discount			$ 230,000
Hercules [Member] \| Hercules Credit Agreement [Member] \| First Fifty Percent [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																6,963
Hercules [Member] \| Hercules Credit Agreement [Member] \| Second Fifty Percent [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																6,963

Note 10 - Stockholders' Equity (Details Textual)											1 Months Ended		6 Months Ended	9 Months Ended	28 Months Ended	55 Months Ended	56 Months Ended
Note 10 - Stockholders' Equity (Details Textual)	Oct. 04, 2017 USD ($)	Jul. 06, 2017 USD ($) $ / shares shares	Jun. 26, 2017 USD ($) $ / shares shares	Jun. 09, 2017 USD ($) $ / shares shares	May 26, 2017	Feb. 14, 2017 USD ($) $ / shares shares	Dec. 20, 2016 USD ($) $ / shares shares	Jun. 13, 2016 USD ($) $ / shares shares	Oct. 02, 2015 USD ($)	Feb. 01, 2013 USD ($)	Sep. 30, 2015 USD ($)	Feb. 25, 2013 USD ($)	Jun. 30, 2017 USD ($) shares	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	May 16, 2017 shares	May 15, 2017 shares	Dec. 31, 2016 $ / shares shares	Jun. 30, 2016 shares	May 31, 2016 shares	May 27, 2015 $ / shares shares	Jan. 15, 2014 $ / shares shares	Feb. 22, 2013 $ / shares shares
Shelf Registration Statement Amount \| $											$ 75,000,000
Common Stock, Shares Authorized														112,500,000	112,500,000	112,500,000	112,500,000			112,500,000	112,500,000	75,000,000
Preferred Stock, Shares Authorized														100,000	100,000	100,000	100,000			100,000	100,000
Aggregate of Common and Preferred Stock, Shares Authorized																					112,600,000
Common Stock, Shares, Outstanding														8,354,679	8,354,679	8,354,679	8,354,679	4,070,172	56,982,418	2,230,118
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number														679,752	679,752	679,752	679,752	200,000	2,400,000	210,023
Class of Warrant or Right, Outstanding														5,528,634	5,528,634	5,528,634	5,528,634	2,400,000	33,500,000	1,487,958
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			506,627	790,410
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.65	$ 2.70										$ 5.33	$ 5.33	$ 5.33	$ 5.33			$ 9.39
Proceeds from Warrant Exercises \| $															$ 800,000	$ 2,100,000
Common Stock, Par or Stated Value Per Share \| $ / shares														$ 0.01	$ 0.01	$ 0.01	$ 0.01			$ 0.01
Aggregate Offering Price, Additions \| $									$ 7,500,000
2013 Warrants, 2014 Warrants, and June 2016 Warrants [Member]
Increase (Decrease) in Fair Value of Warrants \| $				$ 200,000
2015 Warrants [Member]
Increase (Decrease) in Fair Value of Warrants \| $			$ 100,000
July 2017 Direct Offering [Member]
Stock Issued During Period, Shares, New Issues		2,050,000
Share Price \| $ / shares		$ 2.07
Proceeds from Issuance of Common Stock, Gross \| $		$ 4,243,500
July 2017 Direct Offering [Member] \| Pre-Funded Series CCC Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		385,000
Beneficial Ownership Percentage Threshold		9.99%
Class of Warrant or Right, Offered Price of Warrants or Rights \| $ / shares		$ 2.06
Proceeds from Issuance of Warrants \| $		$ 793,100
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 0.01
Class of Warrant or Right, Exercised During Period														385,000
July 2017 Direct Offering [Member] \| Series AAA Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,435,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 2.07
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercisable Period		180 days
Warrants Issued, Expiration Period		5 years 182 days
July 2017 Direct Offering [Member] \| Series BBB Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,435,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 4.75
Warrants Issued, Expiration Period		1 year
July 2017 Direct Offering [Member] \| Series AAA and Series BBB Warrants [Member] \| Subsequent Event [Member]
Proceeds from Issuance of Warrants \| $	$ 16.60
February 14, 2017 Public Offering [Member]
Stock Issued During Period, Shares, New Issues						1,384,704
Shares Issued, Price Per Share \| $ / shares						$ 3.22
Maximum Beneficial Ownership of the Purchaser						9.99%
Proceeds from Issuance of Common Stock \| $						$ 5,000,000
February 14, 2017 Public Offering [Member] \| Series AA Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,177,790
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 3.22
Class of Warrant or Right, Term						5 years
Stock Issued During Period, Shares, Exercise of Warrants													638,809
Proceeds from Warrant Exercises \| $													$ 2,100,000
February 14, 2017 Public Offering [Member] \| Pre-Funded Series BB Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						185,713
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 0.14
Shares Issued, Price Per Share \| $ / shares						$ 3.08
Stock Issued During Period, Shares, Exercise of Warrants														185,713
December 2016 Common Stock Offering [Member]
Stock Issued During Period, Shares, New Issues							367,346
Share Price \| $ / shares							$ 4.90
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							367,343
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares							$ 6.44
Warrants Issued, Expiration Period							5 years 182 days
Proceeds from Issuance of Common Stock \| $							$ 1,800,000
Warrants Exercisable Period							180 days
June 2016 Common Stock Offering [Member]
Stock Issued During Period, Shares, New Issues								165,126
Share Price \| $ / shares								$ 19.04
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								630,252
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								$ 19.60
Proceeds from Issuance of Common Stock \| $								$ 6,000,000
Common Stock, Par or Stated Value Per Share \| $ / shares								$ 0.01
June 2016 Common Stock Offering [Member] \| Series A Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								0.5
Warrants Issued, Expiration Period								5 years 182 days
Warrants Exercisable Period								180 days
June 2016 Common Stock Offering [Member] \| Series C Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								1
Warrants Issued, Expiration Period								1 year
Warrants Exercisable Period								180 days
June 2016 Common Stock Offering [Member] \| Series D Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								0.5
Warrants Issued, Expiration Period								5 years 182 days
Warrants Exercisable Period								180 days
February 2013 Preferred Stock Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																									95,811
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																									$ 74.34
January 2014 Common Stock Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																								64,348
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																								$ 57.40
May 2015 Common Stock Offering [Member] \| 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																							139,284
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																							$ 36.40
ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues																	105,678
Proceeds from Issuance of Common Stock \| $																	$ 7,600,000
Aggregate Offering Price \| $										$ 25,000,000				$ 17,400,000
Commission on Proceeds from ATM Shares Percent												3.00%
Legal Fees \| $												$ 50,000
Aggregate Offering Price, Additions \| $									$ 7,500,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio					14

Note 11 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2007	Dec. 31, 2006
Stock Incentive Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	688,531		688,531		246,031	67,460	31,746	15,873	21,164
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			442,500		178,571	35,714	15,873
Allocated Share-based Compensation Expense	$ 146,896	$ 432,573	$ 951,488	$ 1,331,094
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount				$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 500,000		$ 500,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 36 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 2.69	$ 16.24
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	29,498		29,498

Note 11 - Stock-based Compensation - Stock Option and Restricted Stock (Details)	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Equity awards outstanding, options (in shares) \| shares	210,023
Equity awards outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 59.77
Equity awards granted, options (in shares) \| shares	513,464
Equity awards granted, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.69
Equity awards forfeited, cancelled or expired, options (in shares) \| shares	(43,735)
Equity awards forfeited, cancelled or expired, weighted average exercise price (in dollars per share) \| $ / shares	$ 164.12
Equity awards outstanding, options (in shares) \| shares	679,752
Equity awards outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 9.94
Equity awards outstanding, contractual term (Year)	9 years 146 days
Equity awards exercisable, options (in shares) \| shares	401,920
Equity awards exercisable, weighted average exercise price (in dollars per share) \| $ / shares	$ 13.83
Equity awards exercisable, contractual term (Year)	9 years 47 days
Aggregate intrinsic value of awards exercisable, options \| $
Restricted Stock [Member]
Equity awards outstanding, non-vested restricted stock (in shares) \| shares	4,785
Equity awards outstanding, non-vested restricted stock weighted average grant date fair value (in dollars per share) \| $ / shares	$ 37.42
Equity awards granted, non-vested restricted stock (in shares) \| shares	(3,357)
Equity awards granted, non-vested restricted stock weighted average grant date fair value (in dollars per share) \| $ / shares	$ 42.20
Equity awards forfeited, cancelled or expired, non-vested restricted stock (in shares) \| shares	(1,428)
Equity awards forfeited, cancelled or expired, non-vested restricted stock weighted average grant date fair value (in dollars per share) \| $ / shares	$ 26.18
Equity awards outstanding, non-vested restricted stock (in shares) \| shares
Equity awards outstanding, non-vested restricted stock weighted average grant date fair value (in dollars per share) \| $ / shares
Aggregate intrinsic value of outstanding awards, non-vested restricted stock \| $

Note 11 - Stock-based Compensation - Fair Value of Option Assumptions (Details) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Risk-free interest rate	2.21%
Expected volatility	90.40%
Expected life (Year)	10 years
Expected forfeiture rate		10.00%
Expected dividend yield
Minimum [Member]
Risk-free interest rate		1.55%
Expected volatility		87.40%
Maximum [Member]
Risk-free interest rate		1.87%
Expected volatility		89.10%
Expected life (Year)		10 years

Note 12 - Earn-out Milestone Liability (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Jun. 20, 2014	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability						$ (1,246,151)
Minimum [Member]
Risk Adjusted Assessment of Each Milestone		35.00%	10.00%	50.00%	10.00%	35.00%	10.00%	50.00%	10.00%
Estimated Time to Achieve the Milestone				1 year 182 days	182 days	1 year 91 days	182 days	2 years	182 days
Maximum [Member]
Risk Adjusted Assessment of Each Milestone		80.00%	75.00%	80.00%	75.00%	80.00%	75.00%	80.00%	75.00%
Estimated Time to Achieve the Milestone				2 years	2 years	1 year 273 days	1 year 273 days	2 years 182 days	2 years 182 days
EGEN Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 30,400,000	$ 30,400,000				$ 30,400,000
Business Combination, Consideration Transferred, Liabilities Incurred	$ 13,900,000			$ 13,800,000	$ 13,800,000	12,500,000	$ 14,500,000	$ 13,200,000	$ 13,900,000
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability		$ 1,246,151	$ 662,410			$ 670,172	$ 556,382
EGEN Inc [Member] \| Minimum [Member]
Risk Adjusted Assessment of Each Milestone	10.00%
Estimated Time to Achieve the Milestone	1 year 182 days
EGEN Inc [Member] \| Maximum [Member]
Risk Adjusted Assessment of Each Milestone	67.00%
Estimated Time to Achieve the Milestone	2 years 182 days

Note 12 - Earn-out Milestone Liability - Summary of the Changes in the Earn-out Milestone Liability (Details)	9 Months Ended
	Sep. 30, 2017 USD ($)
Balance	$ 13,188,226
Non-cash benefit from the adjustment for the change in fair value included in net loss	(1,246,151)
Balance	$ 12,518,054

Note 12 - Earn-out Milestone Liability - Schedule of Milestone Risk-adjustment Assessment (Details)	6 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Discount rate	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%
Minimum [Member]
Risk-adjustment assessment	50.00%	10.00%	35.00%	10.00%	50.00%	10.00%
Estimated time to achieve (Year)	1 year 182 days	182 days	1 year 91 days	182 days	2 years	182 days
Maximum [Member]
Risk-adjustment assessment	80.00%	75.00%	80.00%	75.00%	80.00%	75.00%
Estimated time to achieve (Year)	2 years	2 years	1 year 273 days	1 year 273 days	2 years 182 days	2 years 182 days

Note 13 - Warrants - Summary of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Warrants outstanding (in shares) \| shares	1,487,958
Warrants outstanding (in dollars per share) \| $ / shares	$ 9.39
Warrants issued during the nine months ended September 30, 2017 (see Note 10) (in shares) \| shares	6,679,378
Warrants issued during the nine months ended September 30, 2017 (see Note 10) (in dollars per share) \| $ / shares	$ 3.08
Warrants exercised during the nine months ended September 30, 2017 (see Note 10) (in shares) \| shares	(2,638,702)
Warrants exercised during the nine months ended September 30, 2017 (see Note 10) (in dollars per share) \| $ / shares	$ 1.92
Warrants outstanding (in shares) \| shares	5,528,634
Warrants outstanding (in dollars per share) \| $ / shares	$ 5.33
Aggregate intrinsic value of outstanding warrants \| $
Weighted average remaining contractual terms (Year)	3 years 58 days

Note 14 - Contingent Liabilities and Commitments (Details Textual)	1 Months Ended
	Apr. 30, 2017 USD ($) ft²	Jun. 30, 2014 USD ($) ft²	Apr. 30, 2013 USD ($)	Apr. 30, 2012 USD ($)	Jul. 31, 2011 ft²	Sep. 30, 2017 USD ($)	Dec. 31, 2016 USD ($)
Contractual Obligation						$ 907,850	$ 1,115,193
Standby Letters of Credit [Member]
Contractual Obligation Reduction Nineteen Months from Initial Term				$ 50,000
Contractual Obligation Remaining				100,000
Lawrenceville New Jersey [Member]
Area of Real Estate Property \| ft²	7,565	11,500			10,870
Lessee, Operating Lease, Term of Contract					5 years 180 days
Number of Months in Which Free Rent Is Provided	120 days				180 days
Payments for Rent				23,000
Reduction of Escrow Deposit			$ 50,000
Lessee, Operating Lease, Additional Term of Contract	5 years 120 days
Operating Leases, Monthly Rent Payment in First Year	$ 18,900
Operating Leases, Monthly Rent Payment in Final Year	$ 20,500
Lawrenceville New Jersey [Member] \| Standby Letters of Credit [Member]
Contractual Obligation				$ 250,000
Premises Located in Huntsville Alabama [Member]
Lessee, Operating Lease, Term of Contract		120 days
Operating Leases, Monthly Rent Payment		$ 23,200

Note 15 - Technology Development and Licensing Agreements (Details Textual) - USD ($)		3 Months Ended
	Jan. 18, 2013	Mar. 31, 2013	Sep. 30, 2017	Dec. 31, 2016	Mar. 31, 2015
Contractual Obligation			$ 907,850	$ 1,115,193
Deferred Revenue		$ 5,000,000
Deferred Revenue Amortization Period		10 years
Hisun [Member]
Contractual Obligation					$ 685,787
Proceeds from License Fees Received	$ 5,000,000

Note 16 - Subsequent Events (Details Textual) - USD ($)			9 Months Ended	28 Months Ended	55 Months Ended
Note 16 - Subsequent Events (Details Textual) - USD ($)	Oct. 27, 2017	Oct. 04, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2017	Jun. 26, 2017	Jun. 09, 2017	Dec. 31, 2016
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 5.33	$ 5.33	$ 5.33	$ 1.65	$ 2.70	$ 9.39
Class of Warrant or Right, Issued During Period			6,679,378
Proceeds from Warrant Exercises				$ 800,000	$ 2,100,000
Common Stock, Par or Stated Value Per Share			$ 0.01	$ 0.01	$ 0.01			$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						506,627	790,410
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member]
Proceeds from Warrant Exercises		$ 17,000,000
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series AAA and Series BBB Warrants [Member]
Class of Warrant or Right, Exercised During Period		4,665,000
Proceeds from Warrant Exercises		$ 20,000,000
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series AAA Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.07
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series BBB Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.75
Stock Issued During Period, Shares, Exercise of Warrants		205,000
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series DDD Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.20
Class of Warrant or Right, Issued During Period		1,166,250
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercisable Period		180 days
Warrants Issued, Expiration Period		180 days
Subsequent Event [Member] \| October 2017 Exercise Agreements [Member] \| Series AA Warrant [Member]
Stock Issued During Period, Shares, Exercise of Warrants		108,455
Subsequent Event [Member] \| October 2017 Undwriting Offering [Member]
Stock Issued During Period, Shares, New Issues	2,640,000
Common Stock, Par or Stated Value Per Share	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,300,000
Shares Issued, Price Per Share	$ 2.325
Proceeds from Issuance of Common Stock and Warrants	$ 6,600,000
Subsequent Event [Member] \| October 2017 Undwriting Offering [Member] \| Investor Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Class of Warrant or Right, Exercisable Period	180 days
Warrants Issued, Expiration Period	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,320,000
Number of Warrants Sold with Each Share of Common Stock	0.5
Class of Warrant or Right, Offered Price of Warrants or Rights	$ 2.50
Subsequent Event [Member] \| October 2017 Undwriting Offering [Member] \| Investor Warrants [Member] \| Underwriter [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	66,000